Drug Profile
Research programme: ILT-targeted monoclonal antibodies - Tolerx
Alternative Names: TRX385; TRX585Latest Information Update: 17 Jul 2013
Price :
$50
*
At a glance
- Originator Tolerx
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Viral infections
Most Recent Events
- 07 Oct 2011 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 07 Oct 2011 Discontinued - Preclinical for Viral infections in USA (Parenteral)
- 14 Jun 2010 Preclinical development is ongoing in USA